3 2 2 st study of of liv liver f func unctio ion n monit
play

3.2 .2 St Study of of liv liver f func unctio ion n monit onitorin ing in in patient nts r receiv ivin ing agome omelatin ine us using ing the he E Estoni nian H n Healt lth Ins nsur urance Fund und (EHIF) F) dat

0 downloads 6 Views 168 KB Size Report
  1. 3.2 .2 St Study of of liv liver f func unctio ion n monit onitorin ing in in patient nts r receiv ivin ing agome omelatin ine us using ing the he E Estoni nian H n Healt lth Ins nsur urance Fund und (EHIF) F) dat atabase Maia ia U Uusküla la Katrin in K Kurvit its State Agency of Medicines, Estonia 6.12.2016

  2. WHY? HOW? WHAT? SO? 6.12.2016 Agomelatine aRMM 2

  3. WHY? - CAP, authoris ed in 2009 for the treatment of major depres s ive epis odes in adults - Ris k of liver injury known from the s tart - Warning in the SPC – liver function monitoring before the treatment, after 3, 6, 12 and 24 weeks and thereafter when clinically needed – DHPC in October 2012 – DHPC in September 2013 – aRMM in November 2014 (Phys ician’s guide to pres cribing, including a liver monitoring s cheme, and the Patient’s Booklet) 6.12.2016 Agomelatine aRMM 3

  4. HOW? • Pres cription Centre of EHIF - all agomelatine pres criptions of new us ers during 01.01.2012-31.05.2016 New us ers - patients who had not been pres cribed agomelatine during 2011 Only purchas ed pres criptions were included Patients without health ins urance were excluded (non-ins ured patients are charged for tes ts ) 6.12.2016 Agomelatine aRMM 4

  5. HOW? • EHIF Information Sys tem - all liver function tes ts of thes e patients The code field contains AST, ALT, plus ALP, LDH, CPK, GGT, CPK-Mba, Alpha-amylas e Cons equently the res ult may be s lightly more pos itive of the actual s ituation Whether tes ts were performed initiating and during treatment: • compared the tes t date with period of 15 days or 30 days before firs t purchas e; • compared the tes t date with period of +/-15 days or +/-30 days from each purchas e; 6.12.2016 Agomelatine aRMM 5

  6. WHAT? • 5 630 new us ers s tarted with agomelatine (17 377 pres criptions ) • Mainly pres cribed by ps ychiatris ts (55%) and by GP’s (39%) • Mos t commonly pres cribed for depres s ion (31%), anxiety dis orders (21%) and recurrent depres s ive dis orders (17%) • Patients age range - 4-96 years (! Indicated 18-75 years ) – 0.6% (35 ) were children and adoles cent <18 years – 6.4% (363 ) were ≥75 years 6.12.2016 Agomelatine aRMM 6

  7. WHAT? • An average of 3,1 pres criptions per patient and 1,3 packages per pres cription - average of 4 months treatment (median 2 months ) • During the s tudy period the patients had been tes ted 19 026 times, an average 3.8 tes ts per patient 6.12.2016 Agomelatine aRMM 7

  8. WHAT? • Monitoring of LF at the initiation of tre atme nt – In 17% (984) the te s t wa s pe rforme d 15 days be fore s ta rting the tre atme nt, • 23% in childre n a nd a dole s c e nt • 12% in e lde rly (≥75 ye a rs ). – Exte nding the pe riod to 30 days be fore tre atme nt in 23% (1 267) of patie nts the te s t wa s pe rforme d, • 23% in childre n a nd a dole s c e nt • 17% in e lde rly (≥75 ye a rs ). – 54% of the c a s e s the te s ts we re ordinate d by ge ne ra l pra c titione r, 35% by ps ychiatris t. 6.12.2016 Agomelatine aRMM 8

  9. WHAT? • Monitoring of LF during the tre atme nt: – In 37% (2 094) of patie nts at le a s t one te s t wa s pe rforme d during tre atme nt in +/- 15 days of pre s c ription purcha s e. – Exte nding the pe riod to +/- 30 days - in 45% (2 560) of patie nts at le a s t one te s t wa s pe rforme d during tre atme nt. – 1 029 (18%) patie nts re c e ive d agome latine at le a s t for 6 months, • In 66% (684) at le a s t one te s t wa s pe rforme d during tre atme nt • In 4% (42) te s ts we re pe rforme d a c c ording to the live r monitoring s che me 6.12.2016 Agomelatine aRMM 9

  10. 6.12.2016 Agomelatine aRMM 10

  11. 6.12.2016 Agomelatine aRMM 11

  12. SO? As rega rds s tudy re s ults : • Adhe re nc e to the live r monitoring s che me is poor. • Furthe r regulatory a c tion / c ommunic ation is e s s e ntia l 6.12.2016 Agomelatine aRMM 12

  13. SO? As regards s tudy methods - CONS - data it is not always marker s pecific (billing data is bas ed on health care s ervices - many markers may be coded in one code field) - it is not pos s ible to inquire tes t res ults - defining the feas ibility of s tudy characteris tics with EHIF is challenging 6.12.2016 Agomelatine aRMM 13

  14. SO? As regards s tudy methods – PROS EHIF databas e contains data of pres criptions and reimburs ed Hcare s ervices (us ing patient’s ID-code lab tes ts, procedures, diagnos is can be linked) EHIF data can be us ed to inves tigate • what medicines are us ed together • what tes ts /procedures are done prior/during/after T • in which indication and population the medicine is us ed (contraindication, off-label us e) • are pres cribing and dis pens ing res trictions followed (limited amount of medicine per pres cription, dis pens ing time) 6.12.2016 Agomelatine aRMM 14

  15. SO? As regards s tudy methods – when can be us ed? Examples of future inves tigations may be: • Valproate us e and switching to an alternative treatment when patient becomes pregnant • Combined us e of medicines affecting the RAS - us e of alis kiren, AKE inhibitors and ARBs (trends over time) • Is otretinoin and medically s upervis ed pregnancy tes ting prior treatment /before every pres cription, length of the pres cription (1 month) in fertile women 6.12.2016 Agomelatine aRMM 15

  16. Thank you! Any que s tions ? pha rma c ovig@ravimia me t.e e

Recommend Documents


functions as a service
Functions as a Service (a.k.a.

Functions as a Service (a.k.a. Serverless functions) Func unctio tions

func on applica ons calls invoca ons
Func+on applica+ons (calls, invoca+ons)

Racket Func+ons Func+ons: the most important building block in Racket (and

hcc risk prediction
HCC risk prediction what's new? The

The Hong Kong Association for the Study of Liver Diseases International

func ons
Func%ons Func%ons are groups of

Func%ons Func%ons are groups of statements to which you give a

annual general and scientific meeting of the ghana
ANNUAL GENERAL AND SCIENTIFIC MEETING

ANNUAL GENERAL AND SCIENTIFIC MEETING OF THE GHANA ASSOCIATION FOR THE STUDY

the hong kong association for the study of liver d
The Hong Kong Association for the Study

The Hong Kong Association for the Study of Liver D 11/25/18 The Hong Kong

it administra ve controls
IT Administra-ve Controls Week 3

IT Administra-ve Controls Week 3 Organizing an IT Func-on What func-ons are

study of clinical presentation of amoebic liver abscess
Study of Clinical Presentation of

Original Article GCSMC J Med Sci Vol (V) No (I) January-June 2016 Study

analy c window fu func ons
Analy&c Window Fu Func&ons A

Analy&c Window Fu Func&ons A prac'cal look at using analy'c func'ons

michaela rumsey liver week
MICHAELA RUMSEY LIVER WEEK Rebekah

MICHAELA RUMSEY LIVER WEEK Rebekah Rocker Suraiya Chowdhury OVERVIEW Liver

when to stick a needle in 1700s spallanzani ultrasound
When to stick a needle in? 1700s

EUS: past, present and future Update on revised Fukuoka guidelines (2017)

t27 searching for the champion of saliva
T27 Searching for the Champion of

T27 Searching for the Champion of Saliva Collect: 2 mL graduated pipet,

abrhs igem team
ABRHS iGEM Team Project E. Coli Luwak

ABRHS iGEM Team Project E. Coli Luwak Our Team Chris Kuffner Ben Stern

impact of the quality of first food on the digestive
Impact of the Quality of First Food on

Impact of the Quality of First Food on the Digestive Enzymes and Development

enzymes in tortillas
ENZYMES in TORTILLAS and FLAT BREADS

ENZYMES in TORTILLAS and FLAT BREADS Dilek Austin, Ph.D. Baking Technical

an insight into on trend applications of whole grain
An Insight into On-Trend Applications

An Insight into On-Trend Applications of Whole-Grain: Frozen Dough Bread and

an unusual presentation of autoimmune pancreatitis in a
An Unusual Presentation of Autoimmune

CASE REPORT An Unusual Presentation of Autoimmune Pancreatitis in a Patient

presentation
PRESENTATION Albert Chow, MD

FELLOW CASE PRESENTATION Albert Chow, MD Pediatric Rheumatology Fellow

no 1 2 6 amp 9 no 1
No. 1, 2, 6 & 9 No. 1 B D A

2014 DSE BIO 1B-1 No. 1, 2, 6 & 9 No. 1 B D A Some candidates mixed up

breeding for nutritional
Breeding for Nutritional Enhancement

Breeding for Nutritional Enhancement in Potato: Exploring Vitamin B9

bruises bumps and burns it s more than skin deep
Bruises, Bumps and Burns: Its More

Bruises, Bumps and Burns: Its More Than Skin Deep Ada Booth, MD FAAP

dcc 2618 a pan kit and pdgfra switch control inhibitor
DCC-2618, a pan-KIT and PDGFRA switch

2016 EORTC-NCI-AACR December 1, 2016 DCC-2618, a pan-KIT and PDGFRA switch